Symbols / BIAF $3.92 -1.51% bioAffinity Technologies, Inc.
BIAF Chart
About
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 17.63M |
| Enterprise Value | 12.33M | Income | -14.91M | Sales | 6.16M |
| Book/sh | 1.62 | Cash/sh | 1.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | 57 | IPO | — |
| P/E | — | Forward P/E | -6.53 | PEG | — |
| P/S | 2.86 | P/B | 2.42 | P/C | — |
| EV/EBITDA | -1.23 | EV/Sales | 2.00 | Quick Ratio | 2.41 |
| Current Ratio | 2.60 | Debt/Eq | 15.95 | LT Debt/Eq | — |
| EPS (ttm) | -8.66 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | -27.80% | Earnings | 2025-11-14 08:00 | ROA | -75.63% |
| ROE | -3.02% | ROIC | — | Gross Margin | 31.41% |
| Oper. Margin | -196.95% | Profit Margin | -241.96% | Shs Outstand | 4.50M |
| Shs Float | 4.27M | Short Float | 12.14% | Short Ratio | 0.04 |
| Short Interest | — | 52W High | 23.10 | 52W Low | 0.69 |
| Beta | -0.81 | Avg Volume | 8.89M | Volume | 1.46M |
| Target Price | — | Recom | None | Prev Close | $3.98 |
| Price | $3.92 | Change | -1.51% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-01 | down | Maxim Group | Buy → Hold | — |
| 2024-07-23 | init | Maxim Group | — → Buy | $6 |
- Lung cancer sputum test surges 99%, patients avoid risky procedures - Stock Titan Fri, 13 Mar 2026 07
- UGRO, TURB, ANNA, EEIQ, BIAF: These five stocks outpaced big tech with massive March returns - msn.com Sun, 05 Apr 2026 15
- Why Did BIAF Stock Surge 40% Today? - Stocktwits ue, 17 Mar 2026 07
- bioAffinity Technologies shares soar as investors react to upbeat CyPath Lung growth update and 2026 outlook - Quiver Quantitative Mon, 23 Mar 2026 17
- BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - zacks.com hu, 05 Mar 2026 08
- bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF - The Chronicle-Journal hu, 02 Apr 2026 20
- Why Is bioAffinity Technologies Stock Surging Tuesday? - benzinga.com ue, 17 Mar 2026 07
- BIAF stock gains as CyPath sales surge 146% in Q1 - msn.com hu, 02 Apr 2026 09
- BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - Stocktwits Wed, 01 Apr 2026 11
- Doctors drove a 146% jump in orders for this noninvasive lung test - Stock Titan Wed, 01 Apr 2026 12
- Noninvasive lung test spares 71-year-old from risky biopsy - Stock Titan ue, 17 Mar 2026 07
- BIAF Stock Surges 85%, Breaks 200-DMA For The First Time In Nearly A Year – Here’s What’s Driving The Rally - Stocktwits Mon, 23 Mar 2026 07
- bioAffinity to implement 1-for-30 reverse stock split - msn.com Fri, 03 Apr 2026 16
- CyPath Lung sales surge 146% at bioAffinity Technologies (NASDAQ: BIAF) - Stock Titan Wed, 01 Apr 2026 20
- UGRO, TURB, ANNA, EEIQ, BIAF: These Five Stocks Outpaced Big Tech With Massive March Returns - Stocktwits ue, 31 Mar 2026 10
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
6.11
-34.76%
|
9.36
+269.68%
|
2.53
+52627.44%
|
0.00
|
| Operating Revenue |
|
6.10
-34.76%
|
9.35
+272.55%
|
2.51
|
0.00
|
| Cost Of Revenue |
|
4.23
-29.36%
|
5.98
+243.70%
|
1.74
+372680.30%
|
0.00
|
| Reconciled Cost Of Revenue |
|
4.23
-29.36%
|
5.98
+243.70%
|
1.74
+372680.30%
|
0.00
|
| Gross Profit |
|
1.88
-44.32%
|
3.38
+326.79%
|
0.79
+18156.80%
|
0.00
|
| Operating Expense |
|
12.51
+1.42%
|
12.33
+40.70%
|
8.76
+118.28%
|
4.02
|
| Research And Development |
|
2.09
+17.18%
|
1.78
+3.38%
|
1.72
+13.15%
|
1.52
|
| Selling General And Administration |
|
9.91
-0.30%
|
9.94
+46.43%
|
6.79
+173.70%
|
2.48
|
| General And Administrative Expense |
|
—
|
—
|
—
|
—
|
| Other Gand A |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
16.73
-8.63%
|
18.32
+74.34%
|
10.51
+161.61%
|
4.02
|
| Operating Income |
|
-10.63
-18.69%
|
-8.95
-12.29%
|
-7.97
-98.78%
|
-4.01
|
| Total Operating Income As Reported |
|
-10.57
-18.08%
|
-8.95
-12.29%
|
-7.97
-98.78%
|
-4.01
|
| EBITDA |
|
-14.32
-71.87%
|
-8.33
-9.19%
|
-7.63
-36.02%
|
-5.61
|
| Normalized EBITDA |
|
-10.51
-26.12%
|
-8.33
-9.19%
|
-7.63
-31.06%
|
-5.82
|
| Reconciled Depreciation |
|
0.50
-16.64%
|
0.61
+142.65%
|
0.25
+2351.31%
|
0.01
|
| EBIT |
|
-14.82
-65.87%
|
-8.94
-13.41%
|
-7.88
-40.22%
|
-5.62
|
| Total Unusual Items |
|
-3.81
|
—
|
0.00
-100.00%
|
0.21
|
| Total Unusual Items Excluding Goodwill |
|
-3.81
|
—
|
0.00
-100.00%
|
0.21
|
| Special Income Charges |
|
—
|
—
|
0.00
-100.00%
|
0.21
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.21
|
| Net Income |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Pretax Income |
|
-14.87
-64.66%
|
-9.03
-14.05%
|
-7.92
+2.89%
|
-8.15
|
| Net Non Operating Interest Income Expense |
|
-0.02
+71.97%
|
-0.07
-188.07%
|
0.09
+103.42%
|
-2.49
|
| Interest Expense Non Operating |
|
0.04
-52.02%
|
0.09
+149.09%
|
0.04
-98.53%
|
2.53
|
| Net Interest Income |
|
-0.02
+71.97%
|
-0.07
-188.07%
|
0.09
+103.42%
|
-2.49
|
| Interest Expense |
|
0.04
-52.02%
|
0.09
+149.09%
|
0.04
-98.53%
|
2.53
|
| Interest Income Non Operating |
|
0.02
+32.79%
|
0.02
-85.58%
|
0.12
+161.48%
|
0.05
|
| Interest Income |
|
0.02
+32.79%
|
0.02
-85.58%
|
0.12
+161.48%
|
0.05
|
| Other Income Expense |
|
-4.27
-3311896.12%
|
0.00
+100.46%
|
-0.03
+98.32%
|
-1.65
|
| Other Non Operating Income Expenses |
|
-0.46
-358192.25%
|
0.00
+100.46%
|
-0.03
+98.51%
|
-1.87
|
| Gain On Sale Of Security |
|
-3.81
|
—
|
—
|
—
|
| Tax Provision |
|
0.04
+278.04%
|
0.01
-44.51%
|
0.02
+753.72%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Net Income From Continuing Operation Net Minority Interest |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Net Income From Continuing And Discontinued Operation |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Net Income Continuous Operations |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Normalized Income |
|
-11.10
-22.78%
|
-9.04
-13.89%
|
-7.94
+5.13%
|
-8.37
|
| Net Income Common Stockholders |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Diluted EPS |
|
-8.66
+61.51%
|
-22.50
+17.58%
|
-27.30
+49.72%
|
-54.30
|
| Basic EPS |
|
-8.66
+61.51%
|
-22.50
+17.58%
|
-27.30
+49.72%
|
-54.30
|
| Basic Average Shares |
|
1.72
+325.83%
|
0.40
+38.61%
|
0.29
+94.43%
|
0.15
|
| Diluted Average Shares |
|
1.72
+325.83%
|
0.40
+38.61%
|
0.29
+94.43%
|
0.15
|
| Diluted NI Availto Com Stockholders |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Depreciation Amortization Depletion Income Statement |
|
0.50
-16.64%
|
0.61
+142.65%
|
0.25
+2351.31%
|
0.01
|
| Depreciation And Amortization In Income Statement |
|
0.50
-16.64%
|
0.61
+142.65%
|
0.25
+2351.31%
|
0.01
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
8.22
|
| Current Assets |
|
3.97
|
| Cash Cash Equivalents And Short Term Investments |
|
2.82
|
| Cash And Cash Equivalents |
|
2.82
|
| Receivables |
|
0.81
|
| Accounts Receivable |
|
0.78
|
| Other Receivables |
|
0.03
|
| Inventory |
|
0.02
|
| Prepaid Assets |
|
0.17
|
| Other Current Assets |
|
0.15
|
| Total Non Current Assets |
|
4.25
|
| Net PPE |
|
1.99
|
| Gross PPE |
|
2.37
|
| Accumulated Depreciation |
|
-0.37
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
1.54
|
| Machinery Furniture Equipment |
|
0.17
|
| Other Properties |
|
2.18
|
| Leases |
|
0.01
|
| Goodwill And Other Intangible Assets |
|
2.24
|
| Goodwill |
|
1.40
|
| Other Intangible Assets |
|
0.83
|
| Non Current Deferred Assets |
|
—
|
| Other Non Current Assets |
|
0.02
|
| Total Liabilities Net Minority Interest |
|
3.37
|
| Current Liabilities |
|
2.25
|
| Payables And Accrued Expenses |
|
0.90
|
| Payables |
|
0.60
|
| Accounts Payable |
|
0.60
|
| Current Accrued Expenses |
|
0.29
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.86
|
| Current Debt And Capital Lease Obligation |
|
0.46
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.46
|
| Current Deferred Liabilities |
|
0.03
|
| Current Deferred Revenue |
|
0.03
|
| Total Non Current Liabilities Net Minority Interest |
|
1.12
|
| Long Term Debt And Capital Lease Obligation |
|
1.12
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
1.12
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
4.86
|
| Common Stock Equity |
|
4.86
|
| Capital Stock |
|
0.07
|
| Common Stock |
|
0.07
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.31
|
| Ordinary Shares Number |
|
0.31
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
49.39
|
| Retained Earnings |
|
-44.60
|
| Total Equity Gross Minority Interest |
|
4.86
|
| Total Capitalization |
|
4.86
|
| Working Capital |
|
1.72
|
| Invested Capital |
|
4.86
|
| Total Debt |
|
1.58
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
1.58
|
| Net Tangible Assets |
|
2.62
|
| Tangible Book Value |
|
2.62
|
| Interest Payable |
|
—
|
| Preferred Stock Equity |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-9.33
-28.41%
|
-7.26
-20.32%
|
-6.04
-48.32%
|
-4.07
|
| Cash Flow From Continuing Operating Activities |
|
-9.33
-28.41%
|
-7.26
-20.32%
|
-6.04
-48.32%
|
-4.07
|
| Net Income From Continuing Operations |
|
-14.91
-64.93%
|
-9.04
-13.89%
|
-7.94
+2.66%
|
-8.15
|
| Depreciation Amortization Depletion |
|
0.50
-16.64%
|
0.61
+142.65%
|
0.25
+2351.31%
|
0.01
|
| Depreciation And Amortization |
|
0.50
-16.64%
|
0.61
+142.65%
|
0.25
+2351.31%
|
0.01
|
| Other Non Cash Items |
|
—
|
—
|
—
|
3.92
|
| Stock Based Compensation |
|
0.67
-32.15%
|
0.99
+32.16%
|
0.75
+201.23%
|
0.25
|
| Operating Gains Losses |
|
3.81
|
—
|
—
|
-0.21
|
| Gain Loss On Investment Securities |
|
3.81
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.59
+230.70%
|
0.18
-80.05%
|
0.90
+688.76%
|
0.11
|
| Change In Receivables |
|
0.60
+282.35%
|
-0.33
-205.19%
|
0.31
+3575.45%
|
-0.01
|
| Change In Inventory |
|
-0.03
-184.31%
|
-0.01
+29.51%
|
-0.01
-133.65%
|
-0.01
|
| Change In Prepaid Assets |
|
-0.09
+14.71%
|
-0.11
-149.25%
|
0.21
+143.51%
|
-0.49
|
| Change In Payables And Accrued Expense |
|
0.09
-85.14%
|
0.63
+81.70%
|
0.35
-44.08%
|
0.62
|
| Change In Accrued Expense |
|
0.32
+28.27%
|
0.25
-31.24%
|
0.36
-28.57%
|
0.51
|
| Change In Payable |
|
-0.23
-158.93%
|
0.38
+2737.89%
|
-0.01
-112.65%
|
0.11
|
| Change In Account Payable |
|
-0.23
-158.93%
|
0.38
+2737.89%
|
-0.01
-112.65%
|
0.11
|
| Change In Other Working Capital |
|
0.02
+303.10%
|
-0.01
-123.40%
|
0.04
|
—
|
| Investing Cash Flow |
|
-0.06
+23.41%
|
-0.08
+96.42%
|
-2.21
-904.33%
|
-0.22
|
| Cash Flow From Continuing Investing Activities |
|
-0.06
+23.41%
|
-0.08
+96.42%
|
-2.21
-904.33%
|
-0.22
|
| Net PPE Purchase And Sale |
|
-0.06
+23.41%
|
-0.08
-245.31%
|
-0.02
+89.59%
|
-0.22
|
| Purchase Of PPE |
|
-0.06
+23.41%
|
-0.08
-245.31%
|
-0.02
+89.59%
|
-0.22
|
| Capital Expenditure |
|
-0.06
+23.41%
|
-0.08
-245.31%
|
-0.02
+89.59%
|
-0.22
|
| Net Business Purchase And Sale |
|
—
|
0.00
+100.00%
|
-2.19
|
0.00
|
| Purchase Of Business |
|
—
|
0.00
+100.00%
|
-2.19
|
0.00
|
| Financing Cash Flow |
|
14.73
+161.82%
|
5.63
+1731.26%
|
-0.34
-102.41%
|
14.34
|
| Cash Flow From Continuing Financing Activities |
|
14.73
+161.82%
|
5.63
+1731.26%
|
-0.34
-102.41%
|
14.34
|
| Net Issuance Payments Of Debt |
|
-0.37
-118.34%
|
-0.17
+50.92%
|
-0.34
-159.06%
|
0.58
|
| Issuance Of Debt |
|
—
|
0.19
|
0.00
-100.00%
|
1.28
|
| Repayment Of Debt |
|
-0.37
-2.36%
|
-0.36
-4.70%
|
-0.34
+50.36%
|
-0.69
|
| Long Term Debt Issuance |
|
—
|
0.19
|
0.00
-100.00%
|
0.56
|
| Long Term Debt Payments |
|
-0.37
-2.36%
|
-0.36
-4.70%
|
-0.34
-27.78%
|
-0.27
|
| Net Long Term Debt Issuance |
|
-0.37
-118.34%
|
-0.17
+50.92%
|
-0.34
-220.98%
|
0.29
|
| Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.72
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.42
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.30
|
| Net Common Stock Issuance |
|
11.07
+97.26%
|
5.61
|
0.00
-100.00%
|
6.03
|
| Proceeds From Stock Option Exercised |
|
4.81
+232.91%
|
1.45
|
0.00
-100.00%
|
7.79
|
| Net Other Financing Charges |
|
-1.77
-40.42%
|
-1.26
|
—
|
-0.06
|
| Changes In Cash |
|
5.34
+411.40%
|
-1.72
+80.03%
|
-8.59
-185.47%
|
10.05
|
| Beginning Cash Position |
|
1.11
-60.83%
|
2.82
-75.28%
|
11.41
+738.85%
|
1.36
|
| End Cash Position |
|
6.45
+483.54%
|
1.11
-60.83%
|
2.82
-75.28%
|
11.41
|
| Free Cash Flow |
|
-9.39
-27.85%
|
-7.34
-21.17%
|
-6.06
-41.25%
|
-4.29
|
| Interest Paid Supplemental Data |
|
0.02
+32.79%
|
0.02
-52.57%
|
0.04
+1409.76%
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.04
+278.04%
|
0.01
-44.51%
|
0.02
-31.48%
|
0.03
|
| Change In Interest Payable |
|
—
|
0.00
|
0.00
-100.00%
|
0.44
|
| Common Stock Issuance |
|
11.07
+97.26%
|
5.61
|
0.00
-100.00%
|
6.03
|
| Issuance Of Capital Stock |
|
12.06
+114.89%
|
5.61
|
0.00
-100.00%
|
6.03
|
| Net Preferred Stock Issuance |
|
0.99
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
0.99
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-01 View
- 8-K2026-03-26 View
- 8-K2026-03-25 View
- 8-K2026-03-17 View
- 10-K2026-03-16 View
- 8-K2026-03-13 View
- 8-K2026-03-10 View
- 8-K2026-03-06 View
- 8-K2026-03-03 View
- 8-K2026-02-25 View
- 8-K2026-02-19 View
- 8-K2026-02-17 View
- 8-K2026-02-10 View
- 8-K2026-02-09 View
- 8-K2026-02-04 View
- 8-K2026-01-07 View
- 8-K2025-12-22 View
- 8-K2025-12-19 View
- 8-K2025-12-03 View
- 10-Q2025-11-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|